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A B S T R A C T
Background: Clinical studies have reported overexpression of PDE5 and elevation of intracellular cyclic GMP in
various types of cancer cells. ABCC5 transports cGMP out of the cells with high affinity. PDE5 inhibitors prevent
both cellular metabolism and cGMP efflux by inhibiting ABCC5 as well as PDE5. Increasing intracellular cGMP is
hypothesized to promote apoptosis and growth restriction in tumor cells and also has potential for clinical use in
treatment of cardiovascular disease and erectile dysfunction. Vardenafil is a potent inhibitor of both PDE5 and
ABCC5-mediated cGMP cellular efflux. Nineteen novel vardenafil analogs that have been predicted as potent
inhibitors by VLS were chosen for tests of their ability to inhibit ATP- dependent transport of cGMP by measuring
the accumulation of cyclic GMP in inside-out vesicles.
Aim: In this study, we investigated the ability of nineteen new compounds to inhibit ABCC5- mediated cGMP
transport. We also determined the Ki values of the six most potent compounds.
Methods: Preparation of human erythrocyte inside out vesicles and transport assay.
Results: Ki values for six of nineteen compounds that showed more than 50 % inhibition of cGMP transport in the
screening test were determined and ranged from 1.1 to 23.1 μM. One compound was significantly more potent
than the positive control, sildenafil.
Conclusion: Our findings show that computational screening correctly identified vardenafil-analogues that po-
tently inhibit cGMP efflux-pumps from cytosol and could have substantial clinical potential in treatment of
patients with diverse disorders.
1. Introduction
Movement of ions and most other polar or charged molecules across
the plasma membrane depends on specialized membrane transport
proteins. After binding of molecules, they undergo a conformational
change in the process of transporting the solute. Among these proteins,
ATP-binding cassette (ABC) transporters are a large and functionally
diverse class of membrane transporters. ABC transporters have been
classified into seven families according to sequence homologies (ABCA
through ABCG) [1]. They are targeted in studies exploring experimental
treatment of a wide range of conditions, like multidrug resistant Es-
cherichia coli infection and cancer therapy [2–4]. The human ABCC
subfamily; multi resistance proteins (MRP) is capable to export multiple
types of anti-cancer drugs out of the cytoplasm and cause drug re-
sistance to cancer chemotherapy [5,6].
The cyclic nucleotides cAMP and cGMP are involved in physiolo-
gical processes, crucial for normal cellular function. Intracellular con-
centrations are regulated by phosphodiesterase enzymes (PDE) and
export across the cell membrane by ABC transporters [7]. Elimination
of cytosolic cGMP is dependent on PDE5-mediated enzymatic hydro-
lysis and ABCC5-mediated efflux from the cell. Several PDE5-inhibitors
like sildenafil and vardenafil are in clinical use due to their ability to
increase intracellular cGMP. These PDE5 inhibitors also impede the
activity of ABCC5, giving a dual cGMP-elevating effect. This is foun-
dation for their therapeutic potential to treat several conditions from
erectile dysfunction, to various types of cancer.
In the present study, we tested 19 novel compounds chosen by their
potential to inhibit ABCC5. Selection was made based on their struc-
tural similarity to vardenafil and their predicted affinity for the ABCC5
transporter, by molecular modeling and virtual ligand scanning, a
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method used for various studies aiming to detect novel pharmacological
substances [8–11]. Through testing their ability to inhibit ABCC5, we
aimed to detect new pharmacological substances with therapeutic po-
tential.
2. Materials and methods
2.1. Software
The ICM program [12] version 3.6-1e, was used for homology
modeling, compound docking and vardenafil substructure search. The
ICM program package included the ICM VLS add-on and access to
Molcart, a database of chemical structures for ∼4M of commercially
available compounds. The ICM virtual ligand screening technology
provides good tools for accurate individual ligand-protein docking, and
the program has been extensively validated both as a virtual screening
tool, in prediction of ligand pose, docking and screening accuracy
[8–10].
2.2. Homology modeling
To the best of our knowledge, there is no published crystal structure
of the ABCC5 transporter. A homology model of ABCC5 [13], which
was based on the X-ray crystal structure of the Mus musculus ABCB1
[14] (template is available at: https://www.rcsb.org/structure/3g60 -
PDB code 3G60), complexed with the ligand cyclic-tris-(R)-valinesele-
nazole (QZ59-RRR), was used for the present study. (The ABCC5 model
was refined [13] by globally optimizing side chain positions and an-
nealing the backbone using the RefineModel macro of ICM, followed by
the “Regul” option of ICM, and finally energy minimized using the
leaprc.ff03 force field of the AMBER 9 program package [15].
2.3. 4D VLS docking
Energy-based torsional sampling was used to generate additional
conformations of the ligand binding area of ABCC5 in order to in-
vestigate putative ligand binding modes in the highly flexible trans-
porter protein. This computational technique, called “fumigation” [16],
is aimed at generating more “druggable” conformations of ligand
binding pockets. The technique is based on torsional sampling of the
binding pocket side chains in the presence of a repulsive density re-
presenting a generic ligand, using the ICM biased probability Monte
Carlo sampling procedure. The ligand skin mesh of QZ59-RRR from the
template [14] formed the basis for the pocket used for torsional sam-
pling.
The Molcart chemical management system was used to retrieve
compounds with a common substructure as in vardenafil. A database of
vardenafil-like compounds was obtained and used for a 4D VLS docking
into the ABCC5 transporter.
Ligands were prepared in the ICM ligand editor, assigned charges
and converted to 3D when setting up the ligand during the docking
session. A 4D docking procedure was used employing the binding
pocket conformational ensembles, where the pocket ensemble con-
formations are used as an extra, fourth dimension of the ligand sam-
pling space, allowing ligand docking to the multiple binding pocket
conformations in a single docking simulation [17]. The three lowest
energy binding pocket conformations were used in the 4D docking
procedure.
2.4. Vardenafil analogues
Docking score was calculated from interaction energy, where lower
scores corresponds to higher potency. Hits with scores below the
docking score of Vardenafil -24.54 were selected based on druglikeness
and ordered for in vitro testing. The ICM druglikeness score is predicted
based on 5000 marketed drugs from the World Drug Index WDI posi-
tives and 10,000 nondrug compounds negatives. Accordingly, a total of
19 compounds Table 1) were purchased from Enamine (Riga, Latvia)
and eMolecules (San Diego, CA, USA). PubChem (https://pubchem.
ncbi.nlm.nih.gov/) and ChEMBL (https://www.ebi.ac.uk/chembl/)
databases were used to retrieve information about any bioactivity stu-
dies on the two most potent compounds (#8 and #16). For comparison,
bioactivity studies on Vardenafil and Sildenafil were also investigated.
In additionSwissADME (http://www.swissadme.ch/) was used to run
ADME on compounds #8, #16, vardenafil and sildenafil. ICM (https://
onlinelibrary.wiley.com/doi/abs/10.1002/jcc.540150503) was used to
calculate toxicity and drug likeness on the molecules. The ICM Tox
Score is calculated based on known compounds associated with toxi-
city/reactivity with scores based on their perceived toxicity and fre-
quency of appearance in approved drugs. A toxscore> =1. indicates
likely toxicity based on substructure match. The ICM drug-likeness
score is predicted based on 5000 marketed drugs from the World Drug
Index (WDI) (positives) and 10000 non-drug compounds (negatives),
and the score is better if it is positive.
2.5. Preparation of IOV
In the present study, a modified version of the Steck IOV prepara-
tion [[18]] was used. Fresh human EDTA blood was used to produce
IOVs from human erythrocytes. All steps after collecting the blood were
performed at 0–4 °C. The cells were sedimented by centrifugation
2300 g for 15min. Plasma and buffycoat were discarded, and the red
blood cells were washed 3 times by centrifugation at 1000 g 5mM
Tris•HCl, 113mM KCl, pH=8.1. Cells were lysed in 10 volumes of
Table 1
Interactions of the amino acids in the binding site and Vardenafil, Compound 8 and Compound 16.
TMH AA Vardenafil Compound #8 Compound #16
1 Gln190 Piperazine ring – Methoxyphenyl ring
Phe194 Piperazine ring – Methoxyphenyl ring
4 Tyr330 – Cyclopentane ring Bromophenyl ring
5 Val411 Propyl chain of guanosine-like moiety Cyclopentane ring Bromophenyl ring
6 Phe440 Etoxyphenyl group Cyclopentane ring Bromophenyl ring
Asn441 Piperazine ring Piperazine ring Bromophenyl ring
Thr444 – Cyclopentane ring Bromophenyl ring
Lys448 Approximately 10 Å above the binding area of the
ligand
Approximately 10 Å above the binding area of the
ligand
Approximately 10 Å above the binding area of the
ligand
7 Ser872 Guanine-like moiety Guanine-like moiety Guanine-like moiety
Trp879 Piperazine ring Guanine-like moiety Guanine-like moiety
8 Ser921 Propyl chain of guanosine-like moiety – –
12 Tyr1135 Guanine-like moiety Guanine-like moiety Guanine-like moiety
Gln1138 Guanine-like moiety Guanine-like moiety Guanine-like moiety
Phe1145 Guanine-like moiety – –
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5mM TrisHCl, 0.5mM EGTA, 4mM KCl, pH=8.1 and washed by re-
peated centrifugation at 20,000 g for 20min and resuspension in the
same buffer until ghosts were milky white. Vesiculation was initiated by
adding 39 volumes of 500 nM TrisHCl, pH=8.2 to one volume of cell
suspension. The vesiculation was completed by homogenization of ve-
sicles and unsealed ghosts by passing the suspension five times through
a 27 G cannula. IOVs, right-side out vesicles and unsealed vesicles and
ghosts were separated by ultracentrifugation (100.000 × g) over night
using a density gradient from 1,048 g/ml to 1146 g/ml Histodenz
(Sigma-Aldrich, St. Louis, MO, USA) in 5mM Tris, 3 mM KCl, 0.3mM
EGTA. The uppermost band was collected, washed and resuspended in
1.47mM KH2PO4, 81 mM K2HPO4 and 140mM KCl, pH 7.6. Sidedness
was verified using acetylcholinesterase accessibility.
2.6. Transport assay
cGMP is transported out of cells via ABCC5 with a Km value of 2.6
μM [19]. In the present study cGMP uptake into IOVs was determined
for an inhibitor concentration range of 10−3 – 10-7 M. IOVs were in-
cubated for 60min with or without 2.0mM ATP in a mixture containing
20mM Tris•HCl, 10mM MgCl2, 1 mM EGTA, 2 μM [3H]-labeled cGMP,
121mM KCl, pH=8.0 at 37°, and inhibitor in increasing concentra-
tions except for in control samples. The transport process was stopped
with addition of ice-cold 1.47mM KH2PO4, 8,1 mM K2HPO4 and
140mM KCl, pH 7.6. The IOVs were separated from the incubation
medium by filtration (nitrocellulose membrane, 0.22 μm GSWP, Milli-
pore, Billerica, MA, USA). The radioactivity on the filters was quantified
by liquid scintillation (Ultima Gold XR, Packard, Groningen, The
Netherlands) in a Packard 1900 TR Liquid Scintillation analyzer.
2.7. Determination of ki-values
The IC50-values were determined according to Chou [20] and
transformed to Ki-values according to Cheng and Prusoff [21].
2.8. Statistical analysis
We performed statistical comparison of potency of all inhibitors that
inhibited more than 50 % of [3 H]-cGMP uptake by ABCC5 transport
into inside-out vesicles (IOV). Normality and equal variance of data
were confirmed by Shapiro-Wilks test and Brown-Forsythe test. This
was followed by a One Way Analysis of Variance (ANOVA) multiple
comparison versus sildenafil as control substance, using the Holm-Sidak
method. Sildenafil was chosen as control substance over vardenafil due
to higher potency in inhibiting ABCC5 mediated cGMP transport
(Table 3).
3. Results
3.1. In silico (Figs. 1 and 2, Tables 1 and 2)
“Fig. 1 shows Vardenafil docked into the binding site. Amino acid
residues involved with ligand binding included Gln190 and Phe194
(TMH1), Tyr330 (TMH4), Val411 (TMH5), Phe440, Asn441, Thr444
and Lys448 (TMH6), Ser872 and Trp879 (TMH7), Ser921 (TMH8), and
Tyr1135, Gln1138, and Phe1145 (TMH12). The docking score of Var-
denafil was -24.5, and this value was used as a threshold score for the
VLS. Table 1 shows interactions of the amino acids in the binding site
and Vardenafil, Compound 8 and Compound 16. The guanine-like
moieties of these 3 ligands had the same tendency of interacting with
TMHs 7 and 12. The ligands where posed in the the same spacial or-
ientation except for the orientation of the guanine-like ring of Varde-
nafil, which was oriented towards TMH8 (Figs. 1 and 2). Lys448 was
located approximately 10 Å towards the entrance of ABCC5 with its side
chain pointing directly into the transport area.
Table 2 shows the vardenafil-like compounds that were obtained
and used for 4D VLS docking into the ABCC5 transporter. 6 compounds
were found to have potentially high ABCC5 inhibition and were ordered
from eMolecules and Enamine.”
The ADME, Tox and drug likeness data are shown in Table 4. All
compounds were shown to have a high GI absorption theoretically. All
compounds except Compound 16 were predicted to be P-glycoprotein
Fig. 1. (PRINT IN COLOR) Vardenafil (top), compound #8 and compound #16
docked into the binding site of the TMHs of ABCC5 viewed as a section from the
extracellular side. Amino acids with hydrogen bond interactions with sildenafil
are displayed as sticks colored according to atom type (C= light yellow;
H= gray; O= red; N= blue; sulfur= yellow) : Gln190 (TMH1), Asn441
(TMH6), and Gln1138 (TMH12). TMHs are shown as ribbons and are spectrum
color-coded, from purple (TMH1) to red (TMH12).
Fig. 2. (PRINT IN COLOR) Vardenafil, compound #8 and compound #16 dis-
played togheter in the binding site of the TMHs of ABCC5 viewed as a section
from the extracellular side. The guanosine parts of the molecules appeared to
bind with high affinity. Amino acids with hydrogen bond interactions with
sildenafil are displayed as sticks colored according to atom type (C= light
yellow; H=gray; O= red; N= blue; sulfur= yellow) : Gln190 (TMH1),
Asn441 (TMH6), and Gln1138 (TMH12). TMHs are shown as ribbons and are
spectrum color-coded, from purple (TMH1) to red (TMH12).




Compound Formula Molecular weight (g/mol) Structure Supplier Compound ID
#1 C26H30N4O3S CAS: 1080812-22-1 478.60 Enamine Z131669058
#2 C25H28N4O3S CAS: 1190894-94-0 464.57 Enamine Z131675110
#3 C21H18BrN5O2S CAS: 314290-59-0 484.36 Enamine Z15383694
#4 C21H19N5O2S CAS: 331244-89-4 405.47 Enamine Z15383727




#7 C17H20N6O CAS: 1628210-26-3 324.38 Enamine Z729878740
#8 C17H24N6O2 CAS: 1280995-43-8 346.41 Enamine Z1102995434
#9 C17H26N6O2 CAS: 1311601-55-4 346.42 Enamine Z1083966246
#10 C21H24FN5O3S CAS: 1353528-67-2 445.51 Enamine Z218155582
#11 C19H23N5O CAS: 62337-66-0 337.41 Enamine Z1103000948
#12 C20H16CIN5O3S CAS: 189250-11-1 441.891 eMolecules C365-0139
(continued on next page)
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substrates, and CYP inhibition varied. All 4 compounds got a ICM TOx
Score of 0, and Compound 8 had a high drug likeness score, when
compared to Vardenafil and Sildenafil.
3.2. In vitro (Figs. 3–5, Tables 3 and 4)
A single concentration (10 μM) of the 19 identified vardenafil
analogues were tested for their ability to inhibit [3H]-cGMP uptake by
ABCC5 transport into inside-out vesicles (IOV). Sildenafil was in-
troduced as a reference inhibitor and inhibited 83 % of cGMP uptake. In
addition to sildenafil, a total of six compounds inhibited more that 50 %
of cGMP uptake. These were compounds #6 (51 %), #8 (94 %), #9 (75
%), #11 (80 %), #16 (100 %) and #17(69 %). Thus, two of the com-
pounds brought forward by VLS (#8 and #16) showed even higher
potency than sildenafil. Compound #16 blocked the transport com-
pletely and was significantly (p < 0.05) more potent than sildenafil.
Ki-values of the 6 inhibitors achieving a 50 % or higher reduction of
cGMP transport were calculated according to Cheng and Prusoff [21];
using IC50-values, substrate concentration of cGMP (2.0 μM) and Km of
2.6 μM from Orvoll et al. [19]. Sildenafil, which was used as reference
inhibitor, showed a Ki-value of 3.6 μM, while the corresponding values
of compounds 8 and 16were 2.1 μM and 1.1 μM, respectively.
Table 4 shows information about bioactivity studies on compound
8, compound 16, Vardenafil and Sildenafil. No bioactivity studies were
found on compounds 8 and 16, whereas the publications on bioassays
studies on Vardenafil and Sildenafil were above hundreds.
4. Discussion
In the present study, we used molecular modeling techniques to
construct an ABCC5 model and identify interactions with vardenafil
analogues. This allowed us to determine potency and specificity of
candidate drugs, of which the most promising were selected for further
in vitro studies after synthesizing.
Table 2 (continued)
Compound Formula Molecular weight (g/mol) Structure Supplier Compound ID
#13 C22H18CIN5O2S CAS: 57353-08-9 451.929 eMolecules C365-0133
#14 C21H19N5O2S CAS: 189343-71-3 405.473 eMolecules C365-0215
#15 C22H21N5O2S CAS: 194666-84-7 419.499 eMolecules C365-0300
#16 C20H16BrN5O3S CAS: 108667-91-0 486.342 eMolecules G873-0200
#17 C22H21N5O3S CAS: 332869-93-9 435.499 eMolecules G873-0190
#18 C21H18FN5O2S CAS: 852154-45-1 423.463 eMolecules C099-0347
#19 C26H29N5O2S CAS: 1138472-98-6 475.606 eMolecules E960-0870
Vardenafil C23H32N6O4S CAS: 224785-90-4 488.60 eMolecules NC1641891
Table 3
IC50-values ± SEM and Ki-values of six most potent inhibitors and sildenafil.
Order of potency: INH 16 > INH 8>Sildenafil > Vardenafil > INH
9 > INH 17 > INH 6 > INH 11.
Compound IC50 value (μM) Ki value (μM)
# 6 18.0 ± 1.9 10.2 ± 1.4
# 8 3.7 ± 1.9 2.1 ± 0.3
# 9 13.2 ± 1.5 7.5 ± 2.0
# 11 40.9 ± 1.6 23.1 ± 5.5
# 16 2.0 ± 1.3 1.1 ± 0.2
# 17 13.5 ± 1.8 7.7 ± 2.5
Sildenafil 6.4 ± 1.9 3.6 ± 0.7
Vardenafil 7.6 ± 1.8 4.3 ± 1.0
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Modeling of membrane transporters often implies low homology
[22,23]. Further, the template quality must be considered, both in re-
gard to low resolution, and the amphiphilic nature of membrane pro-
teins that cause difficulties in experimental structure determination.
Structural flexibility was accounted for when performing docking and
VLS on our ABCC5 model. A crystal structure of a transporter may not
be a realistic representation of the transporter in its native form, and
transporters may undergo substantial conformational changes during
the transport cycle. Large ranges of motion, changing the accessibility
of the transporter from a cytoplasmic facing to an extracellular facing
conformation, have been revealed from X-ray crystal structures of the
bacterial ABC transporter lipid flippase, MsbA [24]. Induced-fit, de-
monstrated in a study of substrate-induced changes in ABCB1 [25], and
conformational changes due to transport, may be an important part of
ligand recognition. The energy-based torsional sampling ("fumigation")
generated additional conformations of the ligand binding area of
ABCC5, with lower energies than the starting model.
Insight into structural changes of the drug target for yielding a lower
energy drug - drug target complex may elucidate how the conformation
of the binding site contributes to the adoption of an energetically fa-
vorable complex. Ideally, these observations can aid to predict how a
designed drug will fit into the drug target.
The VLS add-on to the Internal Coordinate Mechanics (ICM) pro-
gram [12] (ICM-VLS) has previously been applied to identify new leads
for a number of targets [26,27]. In the present study, the VLS docking
correctly predicted six ligands as having a similar or higher binding
affinity to ABCC5 compared to sildenafil. The most potent vardenafil
analogues, compounds #8 and #16, showed Ki-values of 1.0–2.5 μM,
lower than sildenafil (3.6 μM) and vardenafil (4.3 μM).
The high potency of compound #8 and particularly compound #16
suggest that they could have potential for use in clinical treatment. The
primary indication for administering vardenafil is to treat erectile
dysfunction, by reducing PDE5-mediated cGMP elimination in smooth
muscle cells. Further elevation of intracellular cGMP is achieved with
simultaneous inhibition of ABCC5. Several studies have therefore sug-
gested that inhibition of ABC-transporters could be a valuable strategy
for erectile dysfunction treatment [28,29].
In the present experiment, we used a human erythrocyte model to
investigate cellular efflux of cGMP by ABC-transporters. This is a well-
established model for estimating pharmacological modulation of cGMP
efflux from human cells and show that systemic effect beyond impact
on smooth muscle in the genitourinary system could be expected by
ABCC5 inhibition. We therefore expect that the potent inhibition of
cGMP efflux by compounds #8 and #16 will have systemic effects,
giving treatment potential beyond alleviating erectile dysfunction.
High intracellular levels of cGMP promotes apoptosis and slows cell
growth. This is underlined by that PDE5 and ABCC5 are increased in
many cancer cells, suggesting a selection for increased export and de-
gradation of cGMP in cancer cells [2,3]. Accordingly, the therapeutic
potential of PDE5 and ABCC5-inhibition for anti-cancer treatment lies
in the ability to increase intracellular cGMP levels, promoting apoptosis
and slow cell growth in cancer cells.
In vitro studies indicate that ABCC5 is an important regulator of
NO/cGMP signaling in cardiomyocytes, regulating intracellular cGMP
levels together with PDE-mediated degradation [30]. Elevation of
cGMP in cardiomyocytes is associated with a negative inotropic effect
and protection against ischemia / reperfusion injury [31]. High ex-
pression of ABCC5 in vascular endothelial and smooth muscle cells is
well known, where cGMP levels are important in regulating relaxation
Table 4
Bioactivity studies on Compound 8, Compound 16, Vardenafil and Sildenafil. No bioactivity studies were found on Compounds 8 and 16.
Molecule IUPAC 4 (Bioactivities) 6 (ADME-Tox) Drug likeness































Fig. 3. Showing the ability of 10 μM of the most potent vardenafil analogues to
inhibit [3H]-cGMP uptake by ABCC5 transport in inside-out vesicles (IOV). Two
of the compounds brought forward by VLS (#8 and #16) showed even higher
potency than the reference compound sildenafil. Compound #16 blocked the
transport completely and was significantly (p < 0.05) more potent than sil-
denafil.
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and thus arterial dilatation [30]. Potent ABCC5 inhibitors like com-
pound #8 and #16 could therefore have a potential in treatment of
cardiovascular disorders. In healthy athletes, vardenafil and sildenafil
reduce systolic pulmonary pressure and enhance cardiac output during
exercise [32] and in patients with chronic systolic heart failure, silde-
nafil improves cardiac index [33].
5. Conclusion
Our findings show that computational screening correctly identified
vardenafil-analogues that proved to be potent inhibitors of cGMP ef-
flux-pumps from cytosol. Compounds #8 and #16 provided a more
efficient cGMP efflux inhibition than sildenafil and vardenafil, known
as potent ABCC5 inhibitors. Both compounds could have a substantial
clinical potential. Our results advocate further investigation of their
pharmacokinetic and pharmacodynamic properties.
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